Pancreatology最新文献

{"title":"Clinical impact of intraoperative pancreatic transection margin analysis and additional resection during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma","authors":"Kakeru Tawada ,&nbsp;Yasuhiro Shimizu ,&nbsp;Seiji Natsume ,&nbsp;Tomonari Asano ,&nbsp;Masataka Okuno ,&nbsp;Seiji Ito ,&nbsp;Koji Komori ,&nbsp;Tetsuya Abe ,&nbsp;Kazuo Hara ,&nbsp;Waki Hosoda ,&nbsp;Nobuhisa Matsuhashi","doi":"10.1016/j.pan.2024.10.003","DOIUrl":"10.1016/j.pan.2024.10.003","url":null,"abstract":"<div><h3>Background</h3><div>The prognostic impact of additional resection based on intraoperative frozen section analysis (FSA) of the pancreatic transection margin in patients with pancreatic ductal adenocarcinoma (PDAC) is controversial. The purpose of this study was to evaluate the prognosis based on the results of the first FSA of the pancreatic transection margin (1st FSA) and the clinical significance of additional resection.</div></div><div><h3>Methods</h3><div>Patients who underwent pancreaticoduodenectomy for PDAC from 2000 to 2020 at a single center were included. Patients were divided into 3 groups based on the 1^stFSA. Survival and prognostic factors were analyzed according to the 1^stFSA.</div></div><div><h3>Results</h3><div>A total of 311 patients were included in this study. The 1^stFSA was negative in 272 patients (1^stFSA-R0) and positive in 39 patients [carcinoma in situ (1^stFSA-CIS), 21 patients; invasive carcinoma (1^stFSA-IC), 18 patients]. Additional resections were performed on 37 patients [1^stFSA-CIS, 20 patients; 1^stFSA-IC, 17 patients], and R0 resection was achieved in 34 patients intraoperatively. Comparing median survival time to 1^stFSA-R0 (36.4 months), 1^stFSA-CIS was comparable (27.8 months, p = 0.276), although 1^stFSA-IC was significantly worse (18.8 months, p = 0.001). On multivariate analysis, 1^stFSA-IC was an independent prognostic factor (hazard ratio 2.68, 95 % confidence interval 1.16–6.17, p = 0.020).</div></div><div><h3>Conclusions</h3><div>1^stFSA-CIS and 1^stFSA-R0 had similar OS, implying that additional resection may be acceptable for 1^stFSA-CIS. 1^stFSA-IC was still an independent prognostic factor based on additional resection, and the prognostic significance of additional resection is uncertain for 1^stFSA-IC.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 7","pages":"Pages 1174-1181"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HTF4 modulates the transcription of GID2 to promote the malignant biological behavior of pancreatic cancer","authors":"Wenyang Zhou ,&nbsp;Xin Deng ,&nbsp;Baosheng Wang ,&nbsp;Yifeng Yuan ,&nbsp;Jia Ma ,&nbsp;Xiangpeng Meng","doi":"10.1016/j.pan.2024.08.008","DOIUrl":"10.1016/j.pan.2024.08.008","url":null,"abstract":"<div><h3>Background</h3><div>Helix-loop-helix transcription factor 4 (HTF4) as an anti-cancer target has been reported in many human cancers, but limited data exists regarding the effect of HTF4 in pancreatic cancer. In this study, we aimed to investigate the role of HTF4 in pancreatic cancer.</div></div><div><h3>Methods</h3><div>The expression levels of HTF4 in clinical pancreatic cancer samples were measured. HTF4 was knocked down or overexpressed in pancreatic cancer cells and was subsequently tested for bio-function using in vitro assays and in vivo. The regulation of HTF4 on GID2 was assessed via bioinformatic tools and dual-luciferase reporter assay.</div></div><div><h3>Results</h3><div>We found that HTF4 was highly expressed in pancreatic cancer tissues and correlated with poor patient prognosis. In addition, knocking down HTF4 expression inhibited cell proliferation, migration, and invasion, whereas HTF4 overexpression exerted the opposite effect. Moreover, HTF4 promoted tumor growth and metastasis in pancreatic cancer. Further, HTF4 bound to the GID2 promoter region and promoted transcriptional activation of GID2 in pancreatic cancer cells. GID2 knockdown suppressed HTF4-induced malignant behaviors of pancreatic cancer cells.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that the HTF4/GID2 axis accelerates the progression of pancreatic cancer, providing a potential therapeutic target and prognostic indicator for the treatment of pancreatic cancer patients.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 7","pages":"Pages 1073-1083"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduction of butyrate-producing bacteria in the gut microbiome of Japanese patients with pancreatic cancer","authors":"Makoto Sono ,&nbsp;Kei Iimori ,&nbsp;Munemasa Nagao ,&nbsp;Satoshi Ogawa ,&nbsp;Takahisa Maruno ,&nbsp;Yuki Nakanishi ,&nbsp;Takayuki Anazawa ,&nbsp;Kazuyuki Nagai ,&nbsp;Toshihiko Masui ,&nbsp;Hiroshi Mori ,&nbsp;Koji Hosomi ,&nbsp;Jun Kunisawa ,&nbsp;Haruka Yokota ,&nbsp;Yoshiki Tanaka ,&nbsp;Hiroshi Ohno ,&nbsp;Etsuro Hatano ,&nbsp;Akihisa Fukuda ,&nbsp;Hiroshi Seno","doi":"10.1016/j.pan.2024.09.002","DOIUrl":"10.1016/j.pan.2024.09.002","url":null,"abstract":"<div><h3>Background</h3><div>The incidence of pancreatic cancer is on the rise, and its prognosis remains poor. Recent reports have established a link between the gut and oral microbiome and pancreatic cancer. However, the intricacies of this association within the Japanese population remain unclear. In this study, we investigated the gut and oral microbiomes of Japanese patients with pancreatic cancer, comparing them with those of healthy individuals.</div></div><div><h3>Methods</h3><div>We recruited 30 patients with untreated pancreatic cancer and 18 healthy controls at Kyoto University Hospital (2018–2022). We performed a comprehensive 16S rRNA gene sequencing to analyze their gut and oral microbiomes.</div></div><div><h3>Results</h3><div>Analysis revealed that the diversity of the gut and oral microbiomes of patients with pancreatic cancer was reduced compared to that of the healthy controls. Specifically, we observed an increase in the genus <em>Streptococcus</em> in both the gut and oral microbiomes and a significant decrease in several butyrate-producing bacteria in fecal samples. Moreover, bacteria such as <em>Streptococcus mitis</em> and <em>Holdemanella biformis</em> were present in pancreatic cancer tissues, suggesting that they might influence the carcinogenesis and progression of pancreatic cancer.</div></div><div><h3>Conclusions</h3><div>The gut and oral microbiome differed between patients with pancreatic cancer and healthy controls, with a notable decrease in butyrate-producing bacteria in the gut microbiome of the patients. This suggests that there may be a distinct microbial signature associated with pancreatic cancer in the Japanese population. Further studies are required to elucidate the microbiome's causal role in this cancer and help develop prognostic markers or targeted therapies.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 7","pages":"Pages 1031-1039"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142178148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased needle passes for comparable diagnostic yield in endoscopic ultrasound-guided tissue acquisition for pancreatic stiff lesions measured by elastography","authors":"Tae Seung Lee ,&nbsp;Sang Hyub Lee ,&nbsp;Junyeol Kim,&nbsp;Myeong Hwan Lee,&nbsp;In Rae Cho,&nbsp;Ji Kon Ryu,&nbsp;Yong-Tae Kim,&nbsp;Woo Hyun Paik","doi":"10.1016/j.pan.2024.09.011","DOIUrl":"10.1016/j.pan.2024.09.011","url":null,"abstract":"<div><h3>Background/objectives</h3><div>Pancreatic cancer is characterized by tissue stiffness due to the high concentration of cancer-associated fibroblasts and extracellular matrix. Endoscopic ultrasound-guided tissue acquisition (EUS-TA) is performed to diagnose pancreatic cancer but yields false-negative results attributed to inadequate specimens. EUS-elastography is a real-time assessment method to pancreatic tissue stiffness. This study aims to investigate the correlation between diagnostic yield and the number of needle passes based on the stiffness measured by elastography.</div></div><div><h3>Methods</h3><div>Patients who underwent EUS-TA for pancreatic solid mass were retrospectively reviewed and included in this study. The number of needle passes during EUS-TA was determined based on macroscopic on-site evaluation. Tissue stiffness measurements were taken using EUS-elastography. The primary study outcome was the diagnostic yield. The secondary outcome included the number of needle passes required for a diagnosis.</div></div><div><h3>Results</h3><div>A total of 652 patients were included. The average stiffness differed depending on the location of the tumor, and high-stiffness group had more malignant lesions. Although the diagnostic yield was not significantly different between groups, the number of needle passes was significantly higher in the high-stiffness group (3.6 ± 1.0 vs. 3.2 ± 0.9, p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The higher the stiffness of the pancreatic mass in EUS-elastography, the more needle passes are required to achieve a comparable diagnostic yield.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 7","pages":"Pages 1192-1198"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early selective enteral feeding in combination with active decompression of duodenum in treatment of moderate and severe acute pancreatitis – A proof-of-concept clinical study","authors":"A.A. Kashintsev ,&nbsp;R. Kunda ,&nbsp;V. Proutski","doi":"10.1016/j.pan.2024.09.013","DOIUrl":"10.1016/j.pan.2024.09.013","url":null,"abstract":"<div><h3>Background</h3><div>Acute pancreatitis (AP) is a significant clinical challenge with rising global incidence and substantial mortality rates, necessitating effective treatment strategies. Current guidelines recommend pain and fluid management and early enteral feeding to mitigate complications, yet optimal feeding route remains debated.</div></div><div><h3>Methods</h3><div>We conducted a prospective, randomized, controlled trial at nine centers from October 2020 to May 2023, enrolling 154 patients with moderate to severe AP. Patients were stratified into biliary and non-biliary categories and randomized 1:1 to receive either standard of care (SoC) or SoC plus PandiCath®, a novel catheter enabling selective enteral feeding and duodenal decompression. The primary clinical endpoint (PCE) was a composite of <em>de novo</em> multiple organ dysfunction syndrome (MODS), infectious complications, pancreatic and intestinal fistula formation, bleeding, abdominal compartment syndrome, obstructive jaundice, and AP-related mortality.</div></div><div><h3>Results</h3><div>In the primary modified intention-to-treat analysis, PandiCath® significantly reduced the PCE compared to SoC alone (P = 0.032). The Relative Risk (RR = 0.469, 95 % CI 0.228–0.964) and Number Needed to Treat (NNT = 6.384, 95 % CI 3.349–68.167) indicated its substantial clinical benefit, primarily driven by reduced rates of <em>de novo</em> MODS and infectious complications. These findings were further supported by the evaluation of other populations, including the standard intention-to-treat analysis.</div></div><div><h3>Conclusion</h3><div>PandiCath®, facilitating targeted enteral feeding while isolating and decompressing the duodenum, demonstrates promise in improving outcomes for AP patients at risk of severe complications. Further studies are warranted to validate these findings and explore optimal timing and patient selection for this intervention.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 7","pages":"Pages 1012-1020"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor regarding ‘The duodenum-preserving head resection for chronic pancreatitis of Hans Günter Beger and subsequent modifications’","authors":"Markus W. Büchler,&nbsp;John P. Neoptolemos","doi":"10.1016/j.pan.2024.07.014","DOIUrl":"10.1016/j.pan.2024.07.014","url":null,"abstract":"","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 7","pages":"Pages 1203-1204"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites","authors":"Chiharu Uchiyama ,&nbsp;Taichi Terai ,&nbsp;Minako Nagai,&nbsp;Kota Nakamura,&nbsp;Yuichiro Kohara,&nbsp;Satoshi Yasuda,&nbsp;Yasuko Matsuo,&nbsp;Shunsuke Doi,&nbsp;Takeshi Sakata,&nbsp;Masayuki Sho","doi":"10.1016/j.pan.2024.07.013","DOIUrl":"10.1016/j.pan.2024.07.013","url":null,"abstract":"<div><h3>Background</h3><p>The management of malignant ascites is critical for treating patients with advanced pancreatic cancer. The purpose of this study was to assess the safety of cell-free and concentrated ascites reinfusion therapy (CART) and its impact on the prognosis of patients with advanced pancreatic cancer who have massive malignant ascites.</p></div><div><h3>Methods</h3><p>This study analyzed 47 procedures in 29 patients who underwent CART for ascites caused by pancreatic cancer between 2015 and 2022. Among them, 7 patients who received chemotherapy following CART were classified as the chemotherapy group, while 22 patients without chemotherapy after CART were classified as the palliative care group.</p></div><div><h3>Results</h3><p>Among the 47 procedures, adverse events (AEs) were observed in 9 procedures (19 %). Grade 2 adverse events were observed only in one procedure, manifested as fever. There were no grade 3 or 4 AEs, nor were there any treatment-related deaths. The median survival time was 4.0 months in the chemotherapy group and 0.7 months in the palliative care group (<em>p</em> = 0.004). The albumin level in the chemotherapy group was significantly higher than that in the palliative care group.</p></div><div><h3>Conclusion</h3><p>CART is feasible and might be the optimal option to enable prolonged use of chemotherapy to improve the prognosis for late-stage pancreatic cancer patients.</p></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 6","pages":"Pages 925-929"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141894087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early detection of necrosis in low-enhanced pancreatic parenchyma using contrast-enhanced computed tomography was a better predictor of clinical outcomes than pancreatic inflammation: A multicentric cohort study of severe acute pancreatitis","authors":"","doi":"10.1016/j.pan.2024.07.001","DOIUrl":"10.1016/j.pan.2024.07.001","url":null,"abstract":"<div><h3>Objectives</h3><p>We aim to assess the early use of contrast-enhanced computed tomography<span> (CECT) of patients with severe acute pancreatitis (SAP) using the computed tomography severity index (CTSI) in prognosis prediction. The CTSI combines quantification of pancreatic and extrapancreatic inflammation with the extent of pancreatic necrosis.</span></p></div><div><h3>Methods</h3><p>Post-hoc retrospective analysis of a large, multicentric database (44 institutions) of SAP patients in Japan. The area under the curve (AUC) of the CTSI for predicting mortality and the odds ratio (OR) of the extent of pancreatic inflammation and necrosis were calculated using multivariable analysis.</p></div><div><h3>Results</h3><p>In total, 1097 patients were included. The AUC of the CTSI for mortality was 0.65 (95 % confidence interval [CI:] [0.59–0.70]; p &lt; 0.001). In multivariable analysis, necrosis 30–50 % and &gt;50 % in low-enhanced pancreatic parenchyma (LEPP) was independently associated with a significant increase in mortality, with OR 2.04 and 95 % CI 1.01–4.12 (P &lt; 0.05) and OR 3.88 and 95 % CI 2.04–7.40 (P &lt; 0.001), respectively. However, the extent of pancreatic inflammation was not associated with mortality, regardless of severity.</p></div><div><h3>Conclusions</h3><p>The degree of necrosis in LEPP assessed using early CECT of SAP was a better predictor of mortality than the extent of pancreatic inflammation.</p></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 6","pages":"Pages 827-833"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural history of spontaneous pancreatic portal vein fistulae: A systematic review of the literature","authors":"Natalie E. Griffin ,&nbsp;Morgan Ferrell ,&nbsp;Robert Feldman ,&nbsp;Anil K. Dasyam ,&nbsp;Adam Slivka ,&nbsp;Asif Khalid ,&nbsp;Harkirat Singh ,&nbsp;Charles Gabbert ,&nbsp;Rohit Das ,&nbsp;Sultan Mahmood ,&nbsp;Mordechai Rabinovitz ,&nbsp;Jennifer Chennat ,&nbsp;Stephanie Romutis ,&nbsp;Mary Lou Klem ,&nbsp;Dhiraj Yadav ,&nbsp;Anna Evans Phillips","doi":"10.1016/j.pan.2024.07.016","DOIUrl":"10.1016/j.pan.2024.07.016","url":null,"abstract":"<div><h3>Background</h3><p>Spontaneous pancreatic portal vein fistula (PPVF) - a rare complication of pancreatic inflammation – varies widely in presentation and means of diagnosis but has been previously associated with bleeding complications and mortality. A systematic review of published literature was performed to assess the frequency of outcomes.</p></div><div><h3>Methods</h3><p>A search of electronic databases (PubMed, Ovid MEDLINE, Scopus, EMBASE, gray literature) resulted in 1667 relevant unique manuscripts; 52 met inclusion criteria.</p></div><div><h3>Results</h3><p>A total of 74 unique (male n = 47, 63.5 %) patients were included. Mean age was 53.5 (±11.9) years. History of alcohol use was reported in 55 (74.3 %). Underlying chronic pancreatitis (CP) was present in 49 (66.2 %). In cases where presenting symptoms were reported (n = 57, 77.4 %), the most frequent were abdominal pain (63.5 %), weight loss (14.9 %), rash (12.2 %), nausea/vomiting (12.2 %), and polyarthritis (9.5 %). Computed tomography was the most common imaging modality used to confirm the diagnosis (n = 20, 27.0 %), followed by magnetic resonance cholangiopancreatography (n = 14, 18.9 %). Portal vein thrombosis was reported in 57 (77.0 %), and bleeding events (luminal, variceal, or intra-pseudocyst) were reported in 13(17.6 %) patients. Younger age was associated with higher risk of bleeding events. Mortality was reported in 12 (16.2 %) patients at any time during follow up. Older age and polyarthritis at presentation were associated with mortality.</p></div><div><h3>Conclusions</h3><p>PPVF is a rare and potentially fatal condition, though rates of bleeding complication and death were relatively low in this population. High-quality observational studies are needed to better understand the pathophysiology and natural history of this diagnosis.</p></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 6","pages":"Pages 870-877"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1424390324006963/pdfft?md5=00a4c8f73e9de80a1511514d8d25fd19&pid=1-s2.0-S1424390324006963-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Cystic fibrosis transmembrane conductance regulator (CFTR) variants and CFTR function in patients with pancreatitis","authors":"Paola Melotti,&nbsp;Dora Angyal,&nbsp;Marcel J.C. Bijvelds,&nbsp;Luca Frulloni","doi":"10.1016/j.pan.2024.07.015","DOIUrl":"10.1016/j.pan.2024.07.015","url":null,"abstract":"","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 6","pages":"Pages 971-972"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}